FDA Approved: ZOLINZA — Supplemental Application (Merck Sharp & Dohme LLC)

View source ↗

Summary

FDA approved a supplemental application for ZOLINZA (vorinostat) from Merck Sharp & Dohme LLC.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cutaneous T-cell Lymphoma
• Mycosis Fungoides
• Sézary Syndrome

Drugs mentioned

• Zolinza (vorinostat)

Snippet

SUPPL AP for ZOLINZA (VORINOSTAT)